- 20x speedup in simulating a key pharmaceutical reaction using a quantum-classical hybrid workflow.
- Collaboration between IonQ, AstraZeneca, AWS, and NVIDIA significantly shortens early-stage drug development.
- Suzuki-Miyaura reaction modeled faster and more accurately โ from months to days.
- Proof of concept for quantum-accelerated drug discovery to improve time-to-market and R&D efficiency.
- Showcased at ISC High Performance 2025 in Hamburg, Germany.
IonQ (IONQ.US), in partnership with AstraZeneca, AWS, and NVIDIA, has announced a significant leap in quantum-accelerated computational chemistry. The companies jointly developed and demonstrated a hybrid quantum-classical workflow that achieved over 20x faster simulation times for the Suzuki-Miyaura reaction, a crucial step in small-molecule drug synthesis.
The breakthrough integrates IonQโs Forte quantum processor, NVIDIAโs CUDA-Q platform, and AWS cloud infrastructure. By combining quantum and GPU resources on AWS through Amazon Braket and ParallelCluster, the team cut simulation time from months to days without compromising accuracy.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThis advance showcases how quantum-enhanced computing can solve previously intractable problems in early-stage pharmaceutical R&D, reducing costs and accelerating timelines โ a competitive advantage in a $100B+ drug development industry.
IonQ emphasized that this demonstration, the most complex chemical simulation ever run on its hardware, proves the scalability and commercial utility of hybrid quantum-classical solutions. The company believes this lays the groundwork for broader applications in healthcare, chemistry, and materials science.
IonQ is up 2.45% today, trading at $40.30 per share. Over the past year, the company has increased its market capitalization by as much as 470%.
